CRC Research Update — July 19, 2026
Today's colorectal cancer research highlights
rectal
A collection of 44 issues
Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer
Skip to content
The CRC Digest
▸ TREATMENT
Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer
A multicentre study followed patients treated with bevacizumab combined with chemoradiation before surgery for locally advanced rectal cancer. (Clinical Colorectal Cancer)
This content is informational only and does not constitute
CRC Research Update — July 18, 2026
Today's colorectal cancer research highlights
Baseline ctDNA analyzed for thrombotic risk in locally advanced rectal cancer
Skip to content
The CRC Digest
Baseline ctDNA analyzed for thrombotic risk in locally advanced rectal cancer
Plasma ctDNA was analyzed by droplet digital PCR for tumor-specific mutations including KRAS, NRAS, BRAF, and PIK3CA to explore association with VTE occurrence. (Cancer Treat Res Commun)
This content is informational only and
Jemperli Shows Sustained Response in dMMR/MSI-H Rectal Cancer
Skip to content
The CRC Digest
Jemperli Shows Sustained Response in dMMR/MSI-H Rectal Cancer
Phase 2 data support potential organ preservation in patients with mismatch repair deficient tumors. (Fierce Pharma)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026
CRC Research Update — July 10, 2026
Today's colorectal cancer research highlights
Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer
Skip to content
The CRC Digest
Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer
A case report describes an objective tumor response to the KRAS G12C inhibitor sotorasib combined with EGFR blockade in a patient with advanced NRAS G12C-mutated, mismatch repair-deficient rectal adenocarcinoma refractory to immunotherapy.
Pelvic floor rehabilitation addresses bowel dysfunction and quality of life after rectal cancer
Skip to content
The CRC Digest
Pelvic floor rehabilitation addresses bowel dysfunction and quality of life after rectal cancer
Fourteen survivors shared experiences with structured pelvic floor programs that support bowel function recovery and address psychosocial impacts of low anterior resection syndrome. (Support Care Cancer)
This content is informational only
CRC Research Finding
Skip to content
The CRC Digest
♥ Structured pelvic floor rehabilitation helps survivors manage bowel dysfunction after rectal cancer surgery
A qualitative study of 14 colorectal cancer survivors found that structured pelvic floor rehabilitation programs address low anterior resection syndrome, a common challenge affecting bowel function, psychosocial health, and daily living
CRC Research Update — June 06, 2026
Today's colorectal cancer research highlights